Arcturus Therapeutics (ARCT) Tops Q1 EPS by 6c

Arcturus Therapeutics (NASDAQ: ARCT) reported Q1 EPS of ($1.00), $0.06 better than the analyst estimate of ($1.06). Revenue for the quarter came in at $38.01 million versus the consensus estimate of $30.91 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.

You May Also Be Interested In

• FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
• BofA lists top 5 themes driving next $1tn in incremental semi sales
• Nike names former Pfizer CFO David Denton as new finance chief